← Issue №17/ week of Oct 25, 2026/IBD

Comparative risk of incident Clostridioides difficile infection with vedolizumab versus anti‑TNF in ulcerative colitis: A retrospective cohort study.

From GI Signals issue №17: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD retrospective · n=214 · Oct 19, 2026 · Dig Liver Dis · IF 4.2

Comparative risk of incident Clostridioides difficile infection with vedolizumab versus anti‑TNF in ulcerative colitis: A retrospective cohort study.

New evidenceulcerative colitisbiologicsanti-TNFvedolizumab
Clinical takeawayNo clinical action yet: the study found no statistically significant difference in CDI risk between vedolizumab and anti-TNF in UC, but wide confidence intervals preclude definitive conclusions. Await larger prospective validation before altering practice.
What it foundCDI incidence was 10.89/100 PY with vedolizumab vs 15.09/100 PY with anti-TNF, IDR 0.71 (p=0.427); adjusted HR for CDI was 0.95 (95% CI: 0.41-2.22, p=0.907).
ContextThis study addresses an unresolved question in UC management, comparing CDI risk between vedolizumab and anti-TNF. It neither confirms nor refutes prior assumptions, leaving the issue open for further investigation.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Huang J … Liu T · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
← Read the whole of issue №17 Every paper GI Signals surfaces gets a page like this one. All issues